Cite
Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies.
MLA
Castro-Pearson, Sandra, et al. “Development of a Proteomic Signature Associated with Severe Disease for Patients with COVID-19 Using Data from 5 Multicenter, Randomized, Controlled, and Prospective Studies.” Scientific Reports, vol. 13, no. 1, Nov. 2023, pp. 1–14. EBSCOhost, https://doi.org/10.1038/s41598-023-46343-1.
APA
Castro-Pearson, S., Samorodnitsky, S., Yang, K., Lotfi-Emran, S., Ingraham, N. E., Bramante, C., Jones, E. K., Greising, S., Yu, M., Steffen, B., Svensson, J., Åhlberg, E., Österberg, B., Wacker, D., Guan, W., Puskarich, M., Smed-Sörensen, A., Lusczek, E., Safo, S. E., & Tignanelli, C. J. (2023). Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies. Scientific Reports, 13(1), 1–14. https://doi.org/10.1038/s41598-023-46343-1
Chicago
Castro-Pearson, Sandra, Sarah Samorodnitsky, Kaifeng Yang, Sahar Lotfi-Emran, Nicholas E. Ingraham, Carolyn Bramante, Emma K. Jones, et al. 2023. “Development of a Proteomic Signature Associated with Severe Disease for Patients with COVID-19 Using Data from 5 Multicenter, Randomized, Controlled, and Prospective Studies.” Scientific Reports 13 (1): 1–14. doi:10.1038/s41598-023-46343-1.